Expression of miRNAs-122, -192 and -499 in end stage renal disease associated with acute myocardial infarction

Abstract

IntroductionNew diagnostic tools are needed to accurately detect acute myocardial infarction (AMI) in patients with end stage renal disease (ESRD) presenting with ischemic chest pain. We aimed in this study to investigate circulating miR-122, -192 and -499 expression levels in patients with AMI on top of ESRD and evaluate the potential of these miRNAs as blood-based biomarkers for AMI in patients with ESRD.Material and methodsThe study included 80 ESRD patients without AMI, 80 patients with ESRD associated with AMI and 60 healthy subjects. Assessment of microRNAs was done using SYBR Green based real-time PCR.ResultsLevels of miR-122 were 28-fold and 20-fold higher in controls than in ESRD patients with or without AMI respectively (p < 0.001), while no differences were detected between the two patient groups (p = 0.9). Levels of miR-192 showed a marked increase in ESRD patients with and without AMI compared to the control group (> 500-fold, > 8000-fold respectively, p ≤ 0.001). Patients who developed AMI had lower expression than ESRD patients without AMI (p < 0.001). Non-significant miR-499 elevation was found in ESRD patients without cardiac disease compared to the control group, while highly significant elevation of miR- 499 was demonstrated in ESRD patients who developed AMI compared to other ESRD patients and the control group (> 100-fold, > 350-fold respectively, p = 0.001).ConclusionsAltered expression of miR-122 and -192 may contribute in pathogenesis of ESRD. MiR-192 and -499 may serve as potential biomarkers for AMI in ESRD. Further studies are needed to correlate these miRNAs with disease progression and outcome.

Advances in the Progression and Prognosis Biomarkers of Chronic Kidney Disease

“…Mir-192 is one of the earliest miRNAs that could regulate DNinduced pathological pathways. It was highly expressed in renal tissue and played a key role in renal development and differentiation (Abdelsalam et al, 2019). Later experiments showed that mir-192 could promote the fibrosis of glomeruli and tubules (Mu et al, 2013).…”

Gut microbiota and the pathophysiology of cardiovascular disease

“…f) gut microbiota and chronic kidney disease: CVD and kidney diseases are closely interrelated (e.g., cardiorenal syndrome). Patients with chronic kidney disease (CKD) have a greater risk of CVD complications as well as an increased mortality rate, therefore, in many research environments, they are trying to identify the most appropriate biomarkers of potential complications (29). Studies have confirmed that patients with CKD have a distinctly different composition of gut microbiota.…”